Ginsenoside Rg3 Acts On The G2 Cycle Of The Cell Cycle

The cell turnover cycle is divided into 4 phases, i.e., DNA synthesis prophase (G1 phase), DNA synthesis phase (S phase) versus DNA synthesis anaphase (G2 phase), and cell division phase (M phase).

A large number of scientific trials by scientists in various countries around the world have proved that Rg3, as a protein-energy synthesis promoting factor, acts in the G2 phase of the cell reproductive cycle, It is expressed in multiple gene networks in the regulation, defense, repair, metabolism many systems, to improve the level of energy metabolism, and promote nucleic acid and protein synthesis. And regulate the dynamic balance of protein synthesis and degradation, scavenge harmful metabolites, writhing lesion cells, activate and repair decay cells, deeply mobilize the viability of the body, thereby exerting anti-fatigue, anti-aging, anti-disease, and anticancer effects.

In 2019, at the 22nd National Congress of Clinical Oncology, experts and researchers announced recent advances in anti-tumor angiogenesis therapy. Taking the "Ginsenoside Rg3 medicine anti-tumor angiogenesis "as a special report, it is clear in the report that Ginsenoside Rg3 can inhibit tumor angiogenesis by inhibiting vascular endothelial cell proliferation, migration, inhibiting the signaling pathway of VEGF activity and its signaling, inhibiting degradation of the extravascular matrix, and so on.